A randomized, placebo controlled, investigator and participant-blinded study, investigating safety, tolerability and efficacy of RHH646 in participants with knee osteoarthritis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502821-16-00

Acronym

CRHH646A12201

Enrollment

Registered

2023-06-20

Start date

2023-09-01

Completion date

2025-02-11

Last updated

2025-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Brief summary

Change from baseline in cartilage volume in the index region of the target knee by MRI at Week 52, Adverse Events (AEs) Electrocardiograms (ECGs) Vital signs Hematology, blood chemistry, urinalysis

Detailed description

RHH646 plasma concentrations, Cmin,ss at Week4 and any other PK parameter as appropriate

Interventions

DRUGPlacebo to RHH646 25 mg hard capsules

DRUGRHH646

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline in cartilage volume in the index region of the target knee by MRI at Week 52, Adverse Events (AEs) Electrocardiograms (ECGs) Vital signs Hematology, blood chemistry, urinalysis	—

Secondary

Measure	Time frame
RHH646 plasma concentrations, Cmin,ss at Week4 and any other PK parameter as appropriate	—

Countries

Denmark, Germany, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026